PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12657564-10 2003 These effects of ANG II on UB branching are abrogated by pretreatment with the AT1 receptor antagonist candesartan. candesartan 103-114 angiotensin II receptor, type 1a Mus musculus 79-82 9892143-3 1999 Using mouse proximal tubular cells, this study documents AT1-dependent enhancement (candesartan-inhibitable) of bicarbonate reabsorption and AT2-induced (PD123319- and CGP42112A-inhibitable) decrement of bicarbonate absorption. candesartan 84-95 angiotensin II receptor, type 1a Mus musculus 57-60 9892161-8 1999 Acute AT1 receptor blockade by candesartan reduced tubuloglomerular feedback responses to a flow rate step change of 0 to 30 nl/min by approximately 80% (from 6.1+/-1.4 to 1.3+/-0.4 mmHg). candesartan 31-42 angiotensin II receptor, type 1a Mus musculus 6-9 9933249-9 1999 Moreover, treatment with the selective AT1 antagonist CV-11974 before injury significantly decreased the formation of neointima in only WT mice, whereas treatment with the selective AT2 antagonist PD-123319 before injury had no effects in both animal groups. candesartan 54-62 angiotensin II receptor, type 1a Mus musculus 39-42 9892161-4 1999 Administration of the type 1 angiotensin II (AT1) receptor blocker candesartan (10 mg/kg) to untreated control mice increased renal blood flow by 55% (from 1.8+/-0.2 to 2.8+/-0.2 ml/min) and decreased renal vascular resistance by 42% (from 55+/-7.5 to 31.8+/-2.3 mmHg x min/ml). candesartan 67-78 angiotensin II receptor, type 1a Mus musculus 45-48 31105549-3 2019 Candesartan is a potent specific inhibitor of angiotensin II receptor type 1 (AT1) which limits cerebral inflammation and brain damage in juvenile animals after experimental TBI. candesartan 0-11 angiotensin II receptor, type 1a Mus musculus 46-76 9140053-5 1997 This pressor response was not blocked by pretreatment with sympatholytic agents but was completely inhibited by the AT1-receptor antagonists, losartan and candesartan, suggesting that it is directly mediated by AT1B receptors. candesartan 155-166 angiotensin II receptor, type 1a Mus musculus 116-119 31105549-3 2019 Candesartan is a potent specific inhibitor of angiotensin II receptor type 1 (AT1) which limits cerebral inflammation and brain damage in juvenile animals after experimental TBI. candesartan 0-11 angiotensin II receptor, type 1a Mus musculus 78-81 31105549-5 2019 Despite low cerebral At1 expression, pharmacologic blockade by treatment with candesartan [daily, beginning 30 min after experimental TBI by controlled cortical impact (CCI)] was highly effective in both young and aged animals and reduced histological brain damage by -20% after 5 days. candesartan 78-89 angiotensin II receptor, type 1a Mus musculus 21-24 29615926-8 2018 Results: Candesartan administered ICV during the dark period induced depressor responses which were 40% smaller in BPH/2J than BPN/3J mice (Pstrain < 0.05), suggesting AT1 receptor stimulation may contribute less to BP maintenance in BPH/2J mice. candesartan 9-20 angiotensin II receptor, type 1a Mus musculus 171-174 26144375-8 2015 Candesartan treatment restored the functionality of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis by inhibiting the proinflammatory-redox AT1-mediated mechanism. candesartan 0-11 angiotensin II receptor, type 1a Mus musculus 151-154 27210827-7 2016 Furthermore, only Olmesartan and Candesartan could downregulate the ACE-AngII-AT1 axis and upregulate the ACE2-Ang(1-7)-Mas axis in vitro. candesartan 33-44 angiotensin II receptor, type 1a Mus musculus 78-81 27210827-8 2016 Our data suggest that Olmesartan, Candesartan and Losartan could effectively inhibit pressure overload-induced cardiac remodeling even when with knockdown of Ang II, possibly through upregulation of the expression of the ACE2-Ang(1-7)-Mas axis and downregulation of the expression of the ACE-AngII-AT1 axis. candesartan 34-45 angiotensin II receptor, type 1a Mus musculus 298-301 19845401-4 2009 To explore the role of the angiotensin AT1 receptor in the retinal proteome in diabetes, a subgroup of mice were treated with the AT1 antagonist candesartan. candesartan 145-156 angiotensin II receptor, type 1a Mus musculus 130-133 25395620-6 2015 In wild-type arteries, additional blockade of angiotensin II AT1 receptors with candesartan resulted in an additive reduction of myogenic tone. candesartan 80-91 angiotensin II receptor, type 1a Mus musculus 61-64 22356806-1 2012 BACKGROUND: Several recent studies have shown that angiotensin type 1 receptor (AT1) antagonists such as candesartan inhibit the microglial inflammatory response and dopaminergic cell loss in animal models of Parkinson"s disease. candesartan 105-116 angiotensin II receptor, type 1a Mus musculus 51-78 22356806-1 2012 BACKGROUND: Several recent studies have shown that angiotensin type 1 receptor (AT1) antagonists such as candesartan inhibit the microglial inflammatory response and dopaminergic cell loss in animal models of Parkinson"s disease. candesartan 105-116 angiotensin II receptor, type 1a Mus musculus 80-83 21921024-8 2011 Some mice received an Agtr1 inhibitor (candesartan) or vehicle. candesartan 39-50 angiotensin II receptor, type 1a Mus musculus 22-27 20868737-8 2011 Blocking AT1 with Candesartan led to significant increase in numbers of infiltrating macrophages in the hippocampus 2days post-lesion. candesartan 18-29 angiotensin II receptor, type 1a Mus musculus 9-12 24101294-6 2014 In particular, candesartan and losartan most prominently suppressed myogenic tone, suggesting that AT1 receptors play a central role in myogenic vasoconstriction. candesartan 15-26 angiotensin II receptor, type 1a Mus musculus 99-102 23575826-5 2013 These effects of AngII on nerve responses were blocked by the angiotensin II type 1 receptor (AT1) antagonist CV11974. candesartan 110-117 angiotensin II receptor, type 1a Mus musculus 62-92 23575826-5 2013 These effects of AngII on nerve responses were blocked by the angiotensin II type 1 receptor (AT1) antagonist CV11974. candesartan 110-117 angiotensin II receptor, type 1a Mus musculus 94-97 17622273-4 2007 Treatment with the angiotensin II receptor AT1 antagonist candesartan or the angiotensin II-converting enzyme inhibitor ramipril reduced the blood pressure of the Cx40-/- mice to the same levels seen in wild-type (WT) mice. candesartan 58-69 angiotensin II receptor, type 1a Mus musculus 43-46 19015603-10 2008 Pharmacological blockade of Ang II type 1 receptor (AT1) with candesartan attenuated the development of cardiac dysfunction in ACE2(-/y) mice. candesartan 62-73 angiotensin II receptor, type 1a Mus musculus 28-55 19103228-0 2009 Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. candesartan 0-11 angiotensin II receptor, type 1a Mus musculus 60-63 17356125-9 2007 Knocking out AT(1A) modestly lowers baseline J(HCO(3)) and, like luminal saralasin or candesartan in rabbits, eliminates the J(HCO(3)) response to changes in [CO(2)](BL). candesartan 86-97 angiotensin II receptor, type 1a Mus musculus 13-18